HOUSTON, May 16 /PRNewswire/ -- CardioSoft ( http://www.cardiosoft.com/ ) announced today the recent successful completion of two clinical studies utilizing its new diagnostic cardiology tool, the HFQRS ECG. The CardioSoft HFQRS ECG measures and characterizes high frequency signals present in the QRS portion of the electrocardiogram, offering physicians enhanced diagnostic information that supplements conventional ECG. The core technology was initially developed by researchers at Johnson Space Center and is exclusively licensed from NASA by CardioSoft.
Cardiologists at several Houston area medical institutions, including the Texas Heart Institute, M.D. Anderson Medical Center and the University of Texas Medical Branch, in collaboration with physicians at NASA Johnson Space Center, completed the research studies. In the first study, involving 45 patients undergoing nuclear medicine scanning for myocardial perfusion, the HFQRS ECG correctly predicted ischemia more than 9 out of 10 times. Study results were recently presented at the annual meeting of the International Society of Computerized Electrocardiology. In another study, the HFQRS ECG was found to perform with similar accuracy when used to assess 60 patients for the presence of cardiomyopathy. Results of this study will be presented in June at the 12th Congress of the International Society for Holter and Noninvasive Electrocardiology, in Gdansk, Poland.
The HFQRS ECG is an innovative new tool for noninvasive diagnosis of myocardial ischemia, coronary artery disease, cardiomyopathy and other clinical conditions. Researchers have utilized the HFQRS ECG in a variety of clinical investigations over the past four years with promising results. The two recently completed trials add to a database of reports that now numbers more than a thousand patients studied. Additional investigations are currently underway at academic medical centers in Houston and other locations.
CardioSoft(R) is a privately-held pioneering medical technology company building new ecg products designed to improve the diagnosis and management of heart disease. Recognizing key opportunities to enhance electrocardiology, CardioSoft applies its core expertise in digital signal processing to create innovative solutions to meaningful clinical problems.
News releases and other information about CardioSoft can be found at the company’s website http://www.cardiosoft.com/
CardioSoft(R) and HFQRS-ECG(TM) are trademarks or registered trademarks of the company.
CardioSoft
CONTACT: press, for CardioSoft, daytime, +1-713-623-4009, or eveningsand weekends, +1-832-282-2258
Web site: http://www.cardiosoft.com/